PRKCA (基因名), Protein kinase C alpha type (蛋白名), kpca_human.
产品名称:
Human PRKCA/ Protein kinase C alpha type Recombinant Protein
蛋白激酶C型
货号:
R1380h
商标:
EIAab®
监管等级:
别名:
PKC-A, PKCA, PRKACA
序列号:
P17252
来源:
E.coli
种属:
Human
标签:
His
纯度:
>90% by SDS-PAGE
浓度:
Reconstitution Dependent
形态:
Liquid
内毒素水平:
Please contact protein@eiaab.com The technician for more information.
应用:
存储缓冲液:
50mM NaH2PO4, 500mM NaCl Buffer with 500mM Imidazole, 10%glycerol(PH8.0)
存储:
Store at -20°C. (Avoid repeated freezing and thawing.)
研究领域:
Cancer
R&D 技术数据
更多信息,请参阅手册,或联系我们的技术支持: tech@eiaab.com.
通用注释
亚单元:
Recruited in a circadian manner into a nuclear complex which also includes BMAL1 and RACK1 (By similarity). Interacts with ADAP1/CENTA1, CSPG4 and PRKCABP. Binds to SDPR in the presence of phosphatidylserine. Interacts with PICK1 (via PDZ domain). Interacts with TRIM41.
功能:
Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that is involved in positive and negative regulation of cell proliferation, apoptosis, differentiation, migration and adhesion, tumorigenesis, cardiac hypertrophy, angiogenesis, platelet function and inflammation, by directly phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT, or activating signaling cascade involving MAPK1/3 (ERK1/2) and RAP1GAP. Involved in cell proliferation and cell growth arrest by positive and negative regulation of the cell cycle. Can promote cell growth by phosphorylating and activating RAF1, which mediates the activation of the MAPK/ERK signaling cascade, and/or by up-regulating CDKN1A, which facilitates active cyclin-dependent kinase (CDK) complex formation in glioma cells. In intestinal cells stimulated by the phorbol ester PMA, can trigger a cell cycle arrest program which is associated with the accumulation of the hyper-phosphorylated growth-suppressive form of RB1 and induction of the CDK inhibitors CDKN1A and CDKN1B. Exhibits anti-apoptotic function in glioma cells and protects them from apoptosis by suppressing the p53/TP53-mediated activation of IGFBP3, and in leukemia cells mediates anti-apoptotic action by phosphorylating BCL2. During macrophage differentiation induced by macrophage colony-stimulating factor (CSF1), is translocated to the nucleus and is associated with macrophage development. After wounding, translocates from focal contacts to lamellipodia and participates in the modulation of desmosomal adhesion. Plays a role in cell motility by phosphorylating CSPG4, which induces association of CSPG4 with extensive lamellipodia at the cell periphery and polarization of the cell accompanied by increases in cell motility. Is highly expressed in a number of cancer cells where it can act as a tumor promoter and is implicated in malignant phenotypes of several tumors such as gliomas and breast cancers. Negatively regulates myocardial contractility and positively regulates angiogenesis, platelet aggregation and thrombus formation in arteries. Mediates hypertrophic growth of neonatal cardiomyocytes, in part through a MAPK1/3 (ERK1/2)-dependent signaling pathway, and upon PMA treatment, is required to induce cardiomyocyte hypertrophy up to heart failure and death, by increasing protein synthesis, protein-DNA ratio and cell surface area. Regulates cardiomyocyte function by phosphorylating cardiac troponin T (TNNT2/CTNT), which induces significant reduction in actomyosin ATPase activity, myofilament calcium sensitivity and myocardial contractility. In angiogenesis, is required for full endothelial cell migration, adhesion to vitronectin (VTN), and vascular endothelial growth factor A (VEGFA)-dependent regulation of kinase activation and vascular tube formation. Involved in the stabilization of VEGFA mRNA at post-transcriptional level and mediates VEGFA-induced cell proliferation. In the regulation of calcium-induced platelet aggregation, mediates signals from the CD36/GP4 receptor for granule release, and activates the integrin heterodimer ITGA2B-ITGB3 through the RAP1GAP pathway for adhesion. During response to lipopolysaccharides (LPS), may regulate selective LPS-induced macrophage functions involved in host defense and inflammation. But in some inflammatory responses, may negatively regulate NF-kappa-B-induced genes, through IL1A-dependent induction of NF-kappa-B inhibitor alpha (NFKBIA/IKBA). Upon stimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA), phosphorylates EIF4G1, which modulates EIF4G1 binding to MKNK1 and may be involved in the regulation of EIF4E phosphorylation. Phosphorylates KIT, leading to inhibition of KIT activity. Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN, activating transcription.
亚细胞位置:
Cytoplasm
Cell membrane
Peripheral membrane protein
Mitochondrion membrane
Peripheral membrane protein
Nucleus
该产品尚未在任何出版物中被引用。
[1].
人蛋白激酶C型(PRKCA)重组蛋白是否是无菌的?
蛋白试剂瓶和蛋白保存液是经过高压灭菌的,但也不能保证蛋白是完全无菌的。如果要求蛋白是无菌的,可以用0.2微米的滤器对蛋白进行过滤。
[2].
人蛋白激酶C型(PRKCA)重组蛋白的保存缓冲液是什么?
纯化后的蛋白保存在PBS(58mM Na2HPO4, 17mM NaH2PO4, 68mM NaCl, pH7.4)里,并往里面加入500mM咪唑和10%甘油。
[3].
怎样确定人蛋白激酶C型(PRKCA)重组蛋白的浓度?
蛋白浓度的确定没有一个统一的标准,这主要取决于蛋白的氨基酸序列。伊艾博是根据不同测试的组合来测定蛋白浓度。考马斯亮蓝法、BCA法、氨基酸序列和氨基酸全序列分析法等都用来测定蛋白浓度。
[4].
人蛋白激酶C型(PRKCA)重组蛋白蛋白保存条件是怎样的?
蛋白应保存在 -20℃或 -80℃条件下,为了避免反复冻融,可以将蛋白分装成小份保存。
[5].
人蛋白激酶C型(PRKCA)重组蛋白是否可以用于活体实验?
重组蛋白没有用于任何的活体实验,因此蛋白的活性和半衰期是不确定的。
[6].
人蛋白激酶C型(PRKCA)重组蛋白的保质期是多久?
在适当的保存条件下,从购买之日起蛋白可以稳定保存6-12个月。适当的保存条件是:蛋白保存在-20°C o或 -80℃,保证蛋白的保存浓度高于0.1mg/ml,限制蛋白反复冻融的次数。我们公司常规的质量检测保证所有产品在销售时都有可接受的生物活性。但是我们不能控制终端用户蛋白的保存条件。如果产品在有效期内出现问题,请联系我们的技术支持。
[7].
你们蛋白和抗体的报价是怎么样的?
我们将根据你需要的蛋白和抗体的大小进行报价。
[8].
人蛋白激酶C型(PRKCA)重组蛋白是否能够提供蛋白片段?
我们现有的人的蛋白的序列可以有很多。你可以选择你感兴趣的靶向部分,我们将会按您的需求提供蛋白和抗体。
[9].
人蛋白激酶C型(PRKCA)重组蛋白的货期或发货时间一般是多长?
具体指标的货期需要确定。最快一周,最长可能一个月。
反馈墙
评论数 : 0
所有用户
所有用户
默认排序
默认排序
最近
早期
目前还没有评论。
通知
规格
数量
单价 (¥)
小计 1 (¥)
小计 2:
¥
规格
数量
单价 (¥)